Foghorn Therapeutics Inc.
FHTX
$5.41
-$0.12-2.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.17M | 23.50M | 22.60M | 25.52M | 35.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.17M | 23.50M | 22.60M | 25.52M | 35.19M |
| Cost of Revenue | 88.62M | 90.62M | 94.53M | 98.23M | 99.79M |
| Gross Profit | -64.44M | -67.12M | -71.93M | -72.71M | -64.60M |
| SG&A Expenses | 27.43M | 27.89M | 28.36M | 29.03M | 30.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 116.04M | 118.51M | 122.89M | 127.25M | 130.15M |
| Operating Income | -91.87M | -95.00M | -100.29M | -101.74M | -94.97M |
| Income Before Tax | -75.40M | -80.44M | -86.62M | -89.24M | -83.72M |
| Income Tax Expenses | -- | -- | -- | 1.99M | 2.72M |
| Earnings from Continuing Operations | -75.40 | -80.44 | -86.62 | -91.22 | -86.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.40M | -80.44M | -86.62M | -91.22M | -86.45M |
| EBIT | -91.87M | -95.00M | -100.29M | -101.74M | -94.97M |
| EBITDA | -88.70M | -91.89M | -97.17M | -98.53M | -91.63M |
| EPS Basic | -1.20 | -1.36 | -1.65 | -1.91 | -1.95 |
| Normalized Basic EPS | -0.75 | -0.82 | -1.00 | -1.14 | -1.15 |
| EPS Diluted | -1.20 | -1.36 | -1.65 | -1.91 | -1.95 |
| Normalized Diluted EPS | -0.75 | -0.82 | -1.00 | -1.14 | -1.15 |
| Average Basic Shares Outstanding | 251.30M | 239.90M | 219.48M | 198.84M | 178.27M |
| Average Diluted Shares Outstanding | 251.30M | 239.90M | 219.48M | 198.84M | 178.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |